References
- Page M. The regulatory affairs function as a global development strategic partner. Regulatory Rapporteur 2014;11:4–6.
- Li NL. NDA submission strategy for new chemical entity (NCE) products in Asia Pacific Countries to reduce drug lag. Boston, Massachusetts: DIA 2013 49th Annual Meeting, 2013.
- Keramidas S. Perspectives on the regulatory profession and its critical role in the global health product sector. The Monitor 2013;August:13–16.
- Ukwu HN. Global regulatory affairs—role in the biopharmaceutical industry. Global regulatory systems: a strategic primer for biopharmaceutical product development and registration. CenterWatch; 2011. p 31.
- Berry D, Saias P, Williams B. Unlocking hidden value within regulatory affairs. Delaware: KPMG Healthcare & Life Sciences; 2014.
- Regulatory Affairs Professional Society (RAPS). Regulatory professionals: valued strategic partners. Rockville, Maryland, 2010. Available online at: http://www.prweb.com/releases/2010/StrategicPartners/prweb4705764.htm, accessed 9 December 2015.
- Blair JP, Carroll MC. Local economic development: analysis, practices, and globalization. Thousand Oaks: Sage; 2008.
- Paul SM., Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Disc 2010;9:203–214.
- Rafols I, Hopkins MM, Hoekman J, et al. Big pharma, little science?: A bibliometric perspective on big pharma's R&D decline. Technol Forecast Soc Change 2014;81:22–38.
- Hamburg MA. Shattuck lecture. Innovation, regulation, and the FDA. N Engl J Med 2010;363:2228–2232.
- Murphy E. Inside 23andMe Founder Anne Wojcicki’s $99 DNA Revolution. New York: Fast Company; 2013. Available online at: http://www.fastcompany.com/3018598/for-99-this-ceo-can-tell-you-what-might-kill-you-inside-23andme-founder-anne-wojcickis-dna-r, accessed 9 December 2015.
- Medical Device Innovation Consortium (MDIC). MDIC patient-centered benefit-risk project report: a framework for incorporating information on patient preferences regarding benefit and risk into regulatory assessments of new medical technology. St. Louis Park, MN: MDIC; 2015.
- Claiborne AB, Olson S, editors. Strengthening a workforce for innovative regulatory science in therapeutics development: workshop summary. Washington, D.C.: National Academies Press; 2012.
- Dolgin E. Big pharma moves from “blockbusters” to “niche busters”. Nat Med 2010;16:837.
- DiMasi JA, Grabowski HG, Hansen RW. Cost to develop and win marketing approval for a new drug is $2.6 billion. Boston MA: Tufts University; 2014. Available online at: http://csdd.tufts.edu/news/complete_story/pr_tufts_csdd_2014_cost_study, accessed 9 December 2015
- Parexel Consulting. Drug innovation, approval, market access, and the “new normal”. Emerging FDA review outcome trends for new drugs. Waltham, MA: White Paper; 2010.
- Genentech, Inc. Herceptin development timeline. Available online at: http://www.gene.com/media/product-information/herceptin-development-timeline, accessed 9 December 2015.
- Cohen R. Herceptin®: Breaking New Ground. Cancer biotherapy and radiopharmaceuticals. 1999;14:1–4.
- KPMG LLP. Cutting edge information. Delaware: KPMG; 2012.
- Jaeger J. More compliance departments reporting directly to the CEO. Delaware, USA: Wilmington Compliance Week Inc; 2013. Available online at: http://www.complianceweek.com/news/news-article/more-compliance-departments-reporting-directly-to-the-ceo#.VQroNfnF_DU, accessed 9 December 2015.
- Parloff R. This CEO is out for blood. New York: Fortune; 2014. Available online at: http://fortune.com/2014/06/12/theranos-blood-holmes/, accessed 9 December 2015.
- Carreyrou J. Hot startup Theranos has struggled with its blood-test technology. The Wall Street Journal, Oct 16, 2015.
- Carreyrou J. Hot startup Theranos dials back lab tests at FDA’s behest. The Wall Street Journal; 2015. Available online at: http://www.wsj.com/articles/hot-startup-theranos-dials-back-lab-tests-at-fdas-behest-1444961864, accessed 9 December 2015.
- Pollack A. F.D.A. cites unapproved devices in Theranos review, and faults handling of complaints. The New York Times; 2015. Available online at: http://www.nytimes.com/2015/10/28/business/theranos-quality-control-was-questioned-by-fda.html?_r=0, accessed 9 December 2015.
- Society of Corporate Compliance and Ethics. Minneapolis, MN: The relationship between the board of directors and the compliance and ethics officer. Available online at: http://www.corporatecompliance.org/Resources/View/ArticleId/257/The-Relationship-Between-the-Board-of-Directors-and-the-Compliance-and-Ethics-Officer-1-2-3.aspx, accessed 9 December 2015.
- Ulrich D. Measuring human resources: an overview of practice and a prescription for results. Hum Resource Man 1997;36:303–320.
- Barney JB, Wright PM. On becoming a strategic partner: the role of human resources in gaining competitive advantage. Hum Resource Man 1998;37:31.
- Schuler RS. Repositioning the human resource function: Transformation or demise? Executive 1990;4:49–60.
- Regulatory Affairs Professional Society (RAPS). Rockville, Maryland: Regulatory professionals: valued strategic partners. Available online at: http://www.prweb.com/releases/2010/StrategicPartners/prweb4705764.htm, accessed 9 December 2015.
- Yarbrough C. Why regulatory intelligence is more important than ever. Erie, PA: Pharmaceutical online; 2013. Available online at: http://www.pharmaceuticalonline.com/doc/why-regulatory-intelligence-is-more-important-than-ever-0001, accessed 9 December 2015.
- 23andMe. 23andMe takes first step toward FDA clearance. 23andMe Press Release. 2012. Available online at: https://www.23andme.com/about/press/fda_application/, accessed 9 December 2015.
- 23andMe wants FDA approval. Bonnie Rochman: Time Magazine; 2012. Available online at: http://healthland.time.com/2012/08/02/23andme-wants-fda-approval-for-personal-dna-testing-what-can-it-reveal/, accessed 9 December 2015.
- 23andMe founder Anne Wojcicki’s $99 DNA Revolution. Fast Company; 2013. Available online at: http://www.fastcompany.com/3018598/for-99-this-ceo-can-tell-you-what-might-kill-you-inside-23andme-founder-anne-wojcickis-dna-r, accessed 9 December 2015.
- FDA warning letter 23andMe. Available online at: http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2013/ucm376296.htm, accessed 9 December 2015.
- Park A. Genetic testing company 23andMe returns to market. New York: Time Oct; 2015. Available online at: http://time.com/4080583/23andme-dna-genetic-testing/, accessed 9 December 2015.
- Regulatory Affairs Professional Society (RAPS). Rockville, Maryland: Regulatory professionals: valued strategic partners; 2010. Available online at: http://www.prweb.com/releases/2010/StrategicPartners/prweb4705764.htm, accessed 9 December 2015.
- Madhavan G, Oakley B, Kun LG, et al. Career development in bioengineering and biotechnology. New York, NY: Springer; 2008.
- Robinson R. Is it time for academic preparation of future regulatory affairs professionals? J Med Device Regul 2006;May:18–23.
- Shire S, Swanson C, Drago D, et al. Core competencies provide a roadmap for strengthening regulatory education. Rockville, Maryland: Regulatory Focus; 2014.
- Accreditation Council for Pharmacy Education. Accreditation standards and guidelines. Available online at: https://www.acpe-accredit.org/standards/default.asp, accessed 9 December 2015.
- Jones CT, Browning S, Gladson B, et al. Defining competencies in clinical research: issues in clinical research education and training. Res Practitioner May/June 2012;2:99–107.
- American Association of Colleges of Nursing. The essentials of master's education for advanced practice nursing. Washington, DC: ERIC Clearinghouse; 1996.